{"summary": "Biotech catalyst screen covering multiple small-cap names with PDUFA dates, cash runway, short interest and event timing.", "reason": "The author provides watch/avoid lists based on fundamental data (PDUFA, cash runway, clinical results) for specific assets.", "ideas": [{"symbol": "CAPR", "direction": "watch", "thesis": "Author wrote up Capricor at $4.20 after the 9-3 negative AdCom and ~80% drop, expecting FDA to say no, but FDA extended PDUFA to Nov 22 after additional HOPE-3 follow-up and narrowed the label to upper limb function. Now ~$9.40 with $544M cap, ~$238M cash, 22 months runway, 43% short but only 1.6 days to cover so he would not build a squeeze thesis. Main risk: AdCom still voted against the drug and narrowing the indication does not create new data, so FDA can still say no.", "thesis_short": "CAPR PDUFA Nov 22 with AdCom overhang", "quote": "The AdCom still voted against the drug. Narrowing the indication doesnt create new data. FDA can still say no.", "confidence": 0.7, "sentiment": 0.1, "timeframe": "Nov 22 PDUFA"}, {"symbol": "VNDA", "direction": "watch", "thesis": "Author flags Vanda's imsidolimab for generalized pustular psoriasis with PDUFA Dec 12, citing GEMINI showing 53% skin clearance by week 4 vs 13% placebo. $328M cap, ~$170M liquidity, 14% short. Market dislikes Vanda's FDA history but the data looks interesting.", "thesis_short": "VNDA imsidolimab PDUFA Dec 12, strong data", "quote": "GEMINI showed 53% skin clearance by week 4 vs 13% placebo.", "confidence": 0.65, "sentiment": 0.3, "timeframe": "Dec 12 PDUFA"}, {"symbol": "ANNX", "direction": "watch", "thesis": "Author calls Annexon the biggest binary with Phase 3 topline 2H 2026 in geographic atrophy (ARCHER II), endpoint prevention of 15-letter vision loss. If positive could be first GA drug to show protection of vision rather than only slowing lesion growth. 21% short, ~+/-96% implied move, but only ~12.5 months runway.", "thesis_short": "ANNX ARCHER II GA binary 2H 2026", "quote": "If positive this could be the first GA drug to actually show protection of vision instead of only slowing lesion growth.", "confidence": 0.65, "sentiment": 0.3, "timeframe": "2H 2026"}, {"symbol": "CATX", "direction": "watch", "thesis": "Author calls CATX his favourite with updated Phase 1/2a data at ESMO Oct 23-27, $237M cash vs $357M cap, 33 months runway, 24% short and 18 days to cover.", "thesis_short": "CATX ESMO data with strong cash runway", "quote": "CATX $3.13 is probably my favourite here. Updated Phase 1/2a data, $237M cash vs $357M cap, 33 months runway, 24% short and 18 days to cover.", "confidence": 0.6, "sentiment": 0.4, "timeframe": "ESMO Oct 23-27"}, {"symbol": "KPTI", "direction": "avoid", "thesis": "Author had Karyopharm at $2.04, now $1.79 and still hasn't worked. $41M cap vs ~$65M liquidity, 54% short but only ~7 months runway. Very possible to be right on the drug and still get diluted before getting paid.", "thesis_short": "KPTI dilution risk despite high short interest", "quote": "Very possible to be right on the drug and still get diluted before getting paid.", "confidence": 0.6, "sentiment": -0.4, "timeframe": "unspecified"}, {"symbol": "BFRI", "direction": "watch", "thesis": "Author flags Biofrontera's Ameluz expansion into superficial basal cell carcinoma with PDUFA Sep 28, pivotal showing 65.5% clearance vs 4.8%. Looks high probability on paper but it's a $21M company with ~$5M liquidity, hard to size comfortably.", "thesis_short": "BFRI PDUFA Sep 28, high probability but tiny", "quote": "Pivotal showed 65.5% clearance vs 4.8%. Looks high probability on paper but its a $21M company with around $5M liquidity.", "confidence": 0.6, "sentiment": 0.2, "timeframe": "Sep 28 PDUFA"}], "model": "gemini-3.1-flash-lite", "verified": true, "extraction_model": "deepseek-v4-flash"}